Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025

Kairos Pharma, LTD.

On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.
Presentation covers interim analysis of Phase 2 trial evaluating ENV105 (carotuximab) plus apalutamide in mCRPC.
Trial enrolling 100 men at Cedars-Sinai, City of Hope, and Huntsman Cancer Institute.
On October 1, 2025, Kairos Board approved novation agreements with Cedars-Sinai and Tracon to transfer patent licenses from Enviro to Kairos.
Transferred patents include exclusive licenses for mitochondrial DNA depletion and endoglin antagonism therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.